Bli medlem
Bli medlem

Du är här


Galapagos NV: Galapagos increases share capital through warrant exercises

Mechelen, Belgium; 19 May 2016 - Galapagos NV (Euronext&NASDAQ: GLPG)
announces a share capital increase arising from warrant exercises.
Galapagos issued 140,770 new ordinary shares on 19 May 2016, for a total
capital increase (including issuance premium) of €1,476,401.70.

CEO Onno van de Stolpe exercised 90,000 warrants that were due to expire this
month for a total of €895,500 and has held the resulting shares. He
consequently increased his holding to a total of 628,289 Galapagos shares. In
addition to Onno van de Stolpe, one other Board member exercised 7,500
warrants. Moreover, pursuant to the warrant exercise program of Galapagos'
Executive Committee, Executive Committee members automatically are committed
to exercise a minimum number of warrants, subject to certain conditions.
Pursuant to the rules of this program, two Executive Committee members
exercised an aggregate number of 5,000 warrants, also to hold as shares.

In accordance with Belgian transparency legislation[1], Galapagos notes that
its total share capital currently amounts to €249,394,222.78; the total
number of securities conferring voting rights is 46,109,508, which is also
the total number of voting rights (the "denominator"), and all securities
conferring voting rights and all voting rights are of the same category. The
total number of rights (warrants) to subscribe to not yet issued securities
conferring voting rights is 2,981,227, which equals the total number of
voting rights that may result from the exercise of these warrants. Galapagos
does not have any convertible bonds or shares without voting rights

About Galapagos

Galapagos(Euronext&NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action. Our maturing pipeline comprises Phase 2, Phase 1,
pre-clinical and discovery studies in cystic fibrosis, inflammation,
fibrosis, osteoarthritis and other indications. We have discovered and
developed filgotinib: in collaboration with Gilead we aim to bring this
JAK1-selective inhibitor for inflammatory indications to patients all over
the world. Galapagos is focused on the development and commercialization of
novel medicines that will improve people's lives. The Galapagos group,
including fee-for-service subsidiary Fidelta, has approximately 440
employees, operating from its Mechelen, Belgium headquarters and facilities
in The Netherlands, France, and Croatia. More information at


| Investors: Media: |
| Elizabeth Goodwin Evelyn Fox |
| VP IR&Corporate Director Communications |
| |
|Communications +31 6 53 591 999 |
|+1 781 460 1784 |
| Paul van der Horst |
|Director IR&Business |
|Development |
|+31 6 53 725 199 |
| |
Forward-looking statements

This release may contain forward-looking statements, all of which involve
certain risks and uncertainties. These statements are often, but not always,
made through the use of words or phrases such as "anticipates," "believes,"
"continues," "could," "estimates," "expects," "intends," "may," "plans,"
"seeks," "stands to," "we believe," "will," "we intend," as well as similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors which might cause the actual results,
financial condition and liquidity, performance or achievements of Galapagos,
or industry results, to be materially different from any historic or future
results, financial conditions and liquidity, performance or achievements
expressed or implied by such forward-looking statements. In addition, even if
Galapagos' results, performance, financial condition and liquidity, and the
development of the industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results or
developments in future periods. Among the factors that may result in
differences are the inherent uncertainties associated with competitive
developments, clinical trial and product development activities and
regulatory approval requirements (including that data from Galapagos' ongoing
clinical research programs may not support registration or further
development of its product candidates due to safety, efficacy or other
reasons), Galapagos' reliance on collaborations with third parties, and
estimating the commercial potential of Galapagos' product candidates. A
further list and description of these risks, uncertainties and other risks
can be found in Galapagos' Securities and Exchange Commission (SEC) filings
and reports, including
in Galapagos' most recent annual report on form 20-F filed with the SEC and
subsequent filings and reports filed by Galapagos with the SEC. Given these
uncertainties, the reader is advised not to place any undue reliance on such
forward-looking statements. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based or
that may affect the likelihood that actual results will differ from those set
forth in the forward-looking statements, unless specifically required by law
or regulation.
---------------------------------------[1] Belgian Act of 2 May 2007 on the disclosure of major shareholdings in
issuers whose shares are admitted to trading on a regulated market

GLPG increases share capital through warrant exercises


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.